A new European plan to develop legislation to hold companies accountable for human rights abuses and environmental damage is causing unease for biopharma companies, which rely on various actors in supply chains that could expose them to liability.
Most big European pharma companies already have supplier codes and carry out regular audits. But the new plan, set in motion by the European Parliament in recent weeks, would legally mandate due diligence on human rights and environmental issues.
